Matt Abernethy - 31 Jan 2022 Form 4 Insider Report for NEUROCRINE BIOSCIENCES INC (NBIX)

Role
Chief Financial Officer
Signature
/s/ Darin Lippoldt, Attorney-in-Fact
Issuer symbol
NBIX
Transactions as of
31 Jan 2022
Transactions value $
$0
Form type
4
Date filed
02 Feb 2022, 18:54
Previous filing
03 Dec 2021
Next filing
09 Feb 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction NBIX Stock Option Award $0 +66.4K $0.00 66.4K 31 Jan 2022 Common Stock 66.4K $79.02 Direct F1
transaction NBIX Restricted Stock Unit Award $0 +9.75K $0.00 9.75K 31 Jan 2022 Common Stock 9.75K Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on February 28, 2022 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter.
F2 Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer Common Stock.
F3 The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of January 31, 2023, January 31, 2024, January 31, 2025, and January 31, 2026.